Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 307

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Randomized Phase II Study Comparing Gemcitabine Plus Dacarbazine Versus Dacarbazine Alone in Patients With Previously Treated Soft Tissue Sarcoma: A Spanish Group for Research on Sarcomas Study

García-del-Muro, Xavier, López-Pousa, Antonio, Maurel, Joan, Martín, Javier, Martínez-Trufero, Javier, Casado, Antonio, Gómez-España, Auxiliadora, Fra, Joaquín, Cruz, Josefina, Poveda, Andrés, Meana, Andrés, Pericay, Carlos, Cubedo, Ricardo, Rubió, Jordi, De Juan, Ana, Laínez, Nuria, Carrasco, Juan Antonio, de Andrés, Raquel, Buesa, José M.·2011·Journal of Clinical Oncology

Abstract

Purpose: To assess the activity and toxicity of the combination of gemcitabine plus dacarbazine (DTIC) in patients with advanced soft tissue sarcoma (STS) in a randomized, multicenter, phase II study using DTIC alone as a control arm. Patients and Methods: Patients with previously treated advanced STS were randomly assigned to receive either fixed-dose rate gemcitabine (10 mg/m 2 /min) at 1,800 mg/m 2 followed by DTIC at 500 mg/m 2 every 2 weeks, or DTIC alone at 1,200 mg/m 2 every 3 weeks. The primary end point of the study was progression-free rate (PFR) at 3 months. Results: From November 2005 to September 2008, 113 patients were included. PFR at 3 months was 56% for gemcitabine plus DTIC versus 37% for DTIC alone (P = .001). Median progression-free survival was 4.2 months versus 2 months (hazard ratio [HR], 0.58; 95% CI, 0.39 to 0.86; P = .005), and median overall survival was 16.8 months versus 8.2 months (HR, 0.56; 95% CI, 0.36 to 0.90; P = .014); both favored the arm of gemcitabine plus DTIC. Gemcitabine plus DTIC was also associated with a higher objective response or higher stable disease rate than was DTIC alone (49% v 25%; P = .009). Severe toxicities were uncommon, and treatment discontinuation for toxicity was rare. Granulocytopenia was the more common serious adverse event, but febrile neutropenia was uncommon. Asthenia, emesis, and stomatitis were the most frequent nonhematologic effects. Conclusion: The combination of gemcitabine and DTIC is active and well tolerated in patients with STS, providing in this phase II randomized trial superior progression-free survival and overall survival than DTIC alone. This regimen constitutes a valuable therapeutic alternative for these patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2010.33.6107

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Cited by

See all 307

Metadata

Authors
García-del-Muro, X., López-Pousa, A., Maurel, J., Martín, J., Martínez-Trufero, J., Casado, A., Gómez-España, A., Fra, J., Cruz, J., Poveda, A., Meana, A., Pericay, C., Cubedo, R., Rubió, J., De Juan, A., Laínez, N., Carrasco, J. A., de Andrés, R., & Buesa, J. M.
Venue
Journal of Clinical Oncology
Published
2011-06-20
Volume
29
Issue
18
Pages
2528-2533
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2151384475
Cited by
307
References
11
FWCI
11.63
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Randomized Phase II Study Comparing Gemcitabine Plus Dacarbazine Versus Dacarbazine Alone in Patients With Previously Treated Soft Tissue Sarcoma: A Spanish Group for Research on Sarcomas Study. https://app.cochat.ai/papers/10.1200/jco.2010.33.6107
The paper
García-del-Muro, X., López-Pousa, A., Maurel, J., Martín, J., Martínez-Trufero, J., Casado, A., Gómez-España, A., Fra, J., Cruz, J., Poveda, A., Meana, A., Pericay, C., Cubedo, R., Rubió, J., De Juan, A., Laínez, N., Carrasco, J. A., de Andrés, R., & Buesa, J. M. (2011). Randomized Phase II Study Comparing Gemcitabine Plus Dacarbazine Versus Dacarbazine Alone in Patients With Previously Treated Soft Tissue Sarcoma: A Spanish Group for Research on Sarcomas Study. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2010.33.6107

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.